Opening book details…
Can I read Perifosine (PI3K/AKT Inhibitor) Enhanced Radiation Anti-tumor Efficacy in Prostate Cancer: What is the Optimum Sequence and Timing of the Combined Approach? on EtoBox?
Perifosine (PI3K/AKT Inhibitor) Enhanced Radiation Anti-tumor Efficacy in Prostate Cancer: What is the Optimum Sequence and Timing of the Combined Approach? by Ishiyama, H.; Sun, M.; Gao, Y.; Danforth, R.; Wang, H.; Chunying, Y.; Brinkman, K.; Butler, E.B.; Xu, B.; The, B.S. is a Medicine article available to read on EtoBox.
What is Perifosine (PI3K/AKT Inhibitor) Enhanced Radiation Anti-tumor Efficacy in Prostate Cancer: What is the Optimum Sequence and Timing of the Combined Approach? about?
Purpose/Objective(s): To describe detailed immunologic monitoring of MDSC and Treg in 18 patients with T2N0M0, high-grade soft tissue sarcomas (STS) undergoing phase I/II trial of external beam radiation therapy (EBRT) coordinated with investigational autologous dendritic cells (DC) immunotherapy. Materials/Methods: A total of 5040/180 cGy EBRT and DC was performed according to standardized GMP laboratory procedures (DC progenitor apheresis, ex-vivo expansion and culture, and 4 intratumoral injections of 10 million DC). Immunologic monitoring included peripheral blood mononuclear cells (PBMC) phenotyping by multicolor flow cytometry for evaluating proportions of CD11b + CD14 -CD33 + MDSC and CD4 + CD25 + Foxp3 + Treg. Immune responders were defined as patients induced to produce significant anti-autologous tumor associated antigen (TAA) immune responses determined via ELISPOT assays on patients' PBMC. To further assess correlation between MDSC or Treg level and immune responses to TAA, patients were split into: 1) patients who had MDSC or Treg proportion within 95% confidence interval (CI) of healthy control during or after the treatment; and 2) patients who had increased level of
Who reads Perifosine (PI3K/AKT Inhibitor) Enhanced Radiation Anti-tumor Efficacy in Prostate Cancer: What is the Optimum Sequence and Timing of the Combined Approach??
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Ishiyama, H.; Sun, M.; Gao, Y.; Danforth, R.; Wang, H.; Chunying, Y.; Brinkman, K.; Butler, E.B.; Xu, B.; The, B.S.
- Publisher
- Elsevier Science; Elsevier ; Elsevier BV (ISSN 0360-3016)
- Published
- 2010
- Language
- EN
- Field
- Medicine (Health Sciences)